source
- Mirum's hepatitis D antibody brelovitug meets primary endpoint in phase 3 trialMirum Pharmaceuticals announced that its experimental antiviral monoclonal antibody brelovitug achieved the primary efficacy goal in a phase 3 study for hepatitis D. The trial results continue a s…
- Global scale, regional proximity and unified quality systems boost biologics supply resilienceThe piece explains that creating resilient biomanufacturing supply networks starts with leveraging a global scale of production to spread risk and capacity. It adds that locating facilities closer…